HRT for Menopause: What Every Woman Should Know

Hormone replacement therapy for menopause has been through one of the more dramatic reversals in modern medicine. Before 2002, HRT was the standard of care for menopausal symptoms. After the Women's Health Initiative study results were first reported, prescribing collapsed by more than 80 percent and millions of women were told it was too dangerous to use. Over the twenty years since, careful reanalysis of the WHI data and additional clinical research have substantially revised the picture. For most women starting HRT within 10 years of menopause and under age 60, the benefit-risk profile is favorable, and often dramatically so.

What HRT actually treats

HRT restores the estrogen and progesterone that decline during and after menopause. The primary clinical indications are vasomotor symptoms (hot flashes and night sweats), which HRT reduces by approximately 70 to 90 percent in clinical studies. But HRT also has documented benefits for sleep quality, mood stability, cognitive function, genitourinary symptoms, and bone density preservation.

Bone density protection is underdiscussed. Women lose up to 20 percent of bone density in the first five years after menopause without treatment. HRT initiated within the window can substantially reduce this loss and the associated fracture risk later in life. This is a long-term health benefit that does not show up on a symptom checklist.

Modern HRT is not the HRT the WHI studied

The WHI used conjugated equine estrogens (Premarin) and synthetic medroxyprogesterone acetate, both taken orally. These are not the preparations used in most modern HRT protocols. Today, the preferred protocols use transdermal 17-beta-estradiol (patch or gel) and oral micronized progesterone. The differences matter clinically.

Transdermal estradiol bypasses liver first-pass metabolism, producing VTE (blood clot) risk similar to no HRT at all, rather than the elevated risk seen with oral conjugated estrogens. Micronized progesterone has a more favorable breast tissue profile than synthetic progestogens and better tolerability. Together, the modern protocol is meaningfully safer than what was studied in 2002.

The 10-year window

The most important concept in modern HRT prescribing is the window of opportunity. Women who initiate HRT within 10 years of menopause onset and under age 60 have a favorable benefit-risk profile across nearly every endpoint studied. Starting later, or starting well after menopause, produces a less favorable risk profile, particularly for cardiovascular outcomes.

This does not mean HRT is off the table after age 60 or more than 10 years post-menopause. It does mean the clinical conversation is more nuanced, individual risk factors carry more weight, and the decision deserves careful consideration with your physician.

The role of low-dose testosterone

Women produce testosterone in the ovaries and adrenal glands throughout life. Levels decline roughly 50 percent between the 20s and the 40s, and further after menopause. For women who experience persistent fatigue, reduced libido, or low mood that does not fully resolve with estrogen and progesterone therapy alone, low-dose testosterone can be added.

This is prescribed off-label in the United States (no FDA-approved testosterone product exists for women) but has a growing evidence base. The doses used in women are substantially lower than those used in men. Monitoring of testosterone levels and clinical assessment is part of responsible prescribing.

Contraindications and risk assessment

HRT is not appropriate for every woman. Absolute contraindications include personal history of breast cancer, certain estrogen-sensitive cancers, active or recent venous thromboembolism, certain clotting disorders, active liver disease, and unexplained vaginal bleeding. Family history of breast cancer is not necessarily a contraindication but warrants careful risk discussion.

Your physician reviews your personal and family history, cardiovascular profile, VTE history, and current medications before prescribing. Modern HRT requires careful candidate selection, and responsible prescribing means saying no when the profile suggests it.

What monitoring looks like

HRT monitoring is primarily symptom-driven in the first year. Your physician follows up at roughly 3 months to evaluate symptom response, tolerability, and any side effects, then adjusts dose accordingly. Labs may be ordered when clinically indicated but are not universally required for symptom-based management.

Annual breast health monitoring (including mammography per your physician's recommendation) and pelvic health follow-up are part of ongoing care for women on HRT. Treatment duration is individualized; many women benefit from HRT for 5 to 10 years or longer, reassessed annually.

How to get started

The Eros MD menopause assessment is a physician-led evaluation that includes symptom history, menstrual history, family history, and health review. Your provider determines whether HRT is appropriate, which protocol fits your profile, and what monitoring cadence makes sense. Medication is dispensed from a licensed pharmacy and delivered discreetly. Ongoing provider access is included. This is how menopause care is supposed to work: as an ongoing clinical relationship rather than a one-time prescription.